Surface expression of NKG2D ligands sensitizes tumor cells to immune cell-mediated destruction by engaging NKG2D to activate NK cells and co-stimulate effector T cells initiating an immune response against the incipient tumor (22). The gene discussed is KLRK1; the disease is neoplasm.